Most Expensive Stocks That Doubled in a Year: What Drove Their Explosive Growth

Some stocks soar because of hype. Others climb quietly, then double, even when they’re already expensive. Several high-valuation stocks with strong fundamentals demonstrated that even premium-priced equities can more than double in a short time when breakthrough catalysts align with market momentum.

These weren’t penny stocks or meme plays; they were premium tickers with steep price tags, backed by real fundamentals or breakthrough developments. In this article, we explore which of these giants surged, what fueled their momentum, and what investors can learn about timing, valuation, and smart risk-taking.

Why Expensive Stocks Still Deliver 2× Growth

Investors often assume that high share prices mean limited upside. But as 2025 has demonstrated, price per share is just a number; momentum, narrative, and timing are the real drivers of exponential gains.

For this list, we focused on companies that:

• Trade at premium valuations or hold high share prices relative to peers
• Operate in high-growth sectors such as biotech, fintech, and consumer health
• Are backed by real revenue potential or breakthrough catalysts

These aren’t meme stocks or pump-and-dumps; they’re companies with serious investor backing, and in some cases, institutional credibility.

5 High-Priced Stocks That More Than Doubled in a Year

Below are five standout stocks that more than doubled in value over the past 12 months, despite already carrying premium pricing or steep investor expectations. These companies surprised the market with powerful catalysts, strategic pivots, or aggressive growth trajectories.

1. Summit Therapeutics (SMMT)

A clinical-stage biotech firm focused on novel antibiotic and oncology treatments, Summit gained investor attention for its precision-targeted therapies. Its breakthrough cancer drug development positioned it as a serious contender in the immunotherapy space.

1-Year Range: $6.78 – $36.91

• Current Stock Price: $20.60
• Sector: Biotech
• What Triggered the Stock Surge: Summit shocked the market by announcing positive trial results for ivonescimab, its novel cancer drug targeting non-small cell lung cancer. The treatment’s efficacy, especially when benchmarked against Merck’s Keytruda, sparked a frenzy of investor interest and analyst upgrades.
• Why It Matters: Clinical validation in oncology can instantly change a biotech company’s trajectory. Summit went from niche to headline name with one major breakthrough.

Don't chase the news. Let us curate it.

You get one weekly briefing with only the stories that matter. If the market is quiet, we skip it.

Email address

Get the Weekly Briefing - it's free!

✅ Join readers from Visa, Vanguard, and the FDIC.

2. Robinhood Markets (HOOD)

Robinhood revolutionized retail investing with commission-free trades and a sleek app interface that attracted millions of new investors. As it expanded into crypto, retirement products, and payment services, its long-term vision evolved beyond just stock trading.

1-Year Range: $13.98 – $85.55

• Current Stock Price: $83.03
• Sector: Fintech / Retail Investing
• What Triggered the Stock Surge: Robinhood staged a bold comeback by capitalizing on resurgent crypto trading, margin investing, and new product launches such as retirement accounts and credit cards. Strong earnings, user growth, and improving profitability helped drive the surge.
• Why It Matters: HOOD’s 6× growth shattered the narrative that post-meme era fintech was finished. Its return to relevance proves the power of innovation in a crowded sector.

3. Hims & Hers Health (HIMS)

Hims & Hers is a direct-to-consumer telehealth company delivering accessible treatments across wellness, mental health, and weight loss. Its recurring subscription model and digital-first strategy made it a standout in the modern healthcare landscape.

1-Year Range: $13.47 – $72.98

• Current Stock Price: $49.41
• Sector: Healthtech / DTC Wellness
• What Triggered the Stock Surge: The company expanded rapidly into weight loss programs, launching GLP-1 medication access and driving record-breaking subscription growth. Combined with strategic brand positioning in sexual wellness and mental health, HIMS became a breakout growth story.
• Why It Matters: Investors embraced the DTC health trend, especially with recurring digital revenue. HIMS turned a niche offering into a multibillion-dollar opportunity.

4. FuboTV (FUBO)

FuboTV offers a sports-centric streaming platform tailored for cord-cutters seeking live events, original content, and exclusive broadcasts. With a niche focus and growing ad revenues, it remains a speculative favorite among OTT investors.

1-Year Range: $1.15 – $6.45

• Current Stock Price: $3.53
• Sector: Streaming / Live Sports
• What Triggered the Stock Surge: FuboTV improved its fundamentals with smarter cost control, better content licensing, and growth in ad-supported revenues. As competition thinned, its niche in live sports streaming became more defensible.
• Why It Matters: From penny stock territory to nearly 6× growth, Fubo proved that targeted content and disciplined spending still win in the OTT space.

5. Groupon (GRPN)

Groupon connects consumers with local deals and experiences, leveraging mobile commerce and data to reignite its brand. Though once considered outdated, its operational turnaround and renewed focus on profitability sparked fresh investor optimism.

1-Year Range: $7.76 – $41.26

• Current Stock Price: $34.45
• Sector: Ecommerce / Local Deals
• What Triggered the Stock Surge: Groupon executed a rare turnaround. With lean operations, app improvements, and leadership changes, the company re-engaged local merchants and grew its take rate. Quarterly earnings finally beat expectations.
• Why It Matters: Once considered obsolete, Groupon’s renaissance shows how even legacy platforms can capitalize on brand equity with operational focus.

What Investors Can Learn

Stocks that double in a year often seem like anomalies, especially when they already carry steep price tags. But as these five companies have proven, explosive growth is still possible when breakthrough moments align with business execution. For investors, the key is not just chasing performance, but understanding why the surge happened and whether it can continue.

• Catalysts drive the climb, price does not limit it: Expensive stocks can deliver huge returns if they’re tied to game-changing products, market timing, or business model shifts. The more clearly defined the catalyst, the stronger the conviction behind the price surge.
• Look for recurring revenue or disruptive potential: Hims & Hers and Robinhood succeeded in part due to scalable digital models. Subscription revenue, platform engagement, or product-led growth offer signs that growth is sustainable, not just speculative.
• Risk is still real: While doubling sounds attractive, these stocks remain volatile. Many of them, like Fubo or Groupon, still operate in high-risk categories and may face execution hurdles or competition.
• Track momentum early, but don’t chase blindly: The biggest gains often come when the market hasn’t yet fully priced in the story. Instead of buying after the spike, smart investors spot signals, like clinical trials, earnings surprises, or product rollouts, early.

Expensive Stocks to Watch Next

Some high-valuation stocks exhibit characteristics seen in past outperformers, such as strong narratives, large addressable markets, and innovation-driven momentum, which may position them for future breakout potential.

• SoundHound AI (SOUN) – An AI-driven voice technology company growing fast in the automotive and enterprise sectors. Its strategic partnerships and AI scalability are being closely watched.
• Zscaler (ZS) – A cybersecurity leader in zero-trust architecture with consistent top-line growth. Institutions value it for both its pricing power and sector resilience.
• Novo Nordisk (NVO) – Riding the global weight loss drug trend, its premium valuation is tied to growing GLP-1 demand across multiple regions.

Each of these stocks shares characteristics seen in past doublers: strong narrative, big total addressable markets (TAM), and clear catalysts.

Conclusion: Doubling Is Rare, But Not Random

High-priced stocks that double in a year may seem like lightning strikes, but they’re rarely random. More often, they’re the result of clear growth signals, timely investor sentiment, and companies executing at the right moment. For investors seeking outsized returns, the lesson is simple: price isn’t the barrier, lack of conviction and research is.